Skip to main content

PharmExpert Global

Medicine and device safety updates | 20 November 2026

Official communications and updates published on 19–20 November 2026, including New Zealand actions with earlier commencement dates and the English translation of Japan’s September bulletin. Related issues in different jurisdictions are presented as national actions, not independent new signals.

Tirzepatide: updated oral-contraception recommendations

AEMPS · MUH (FV), 04/2026

AEMPS recommends that women using oral contraceptives add a barrier method for four weeks after starting tirzepatide and for four weeks after each dose increase, or switch to a non-oral method. Evidence on oral-contraceptive pharmacokinetics and effectiveness in the relevant population is limited. The existing pregnancy precautions remain. These are the Spanish regulator’s recommendations of 19 November.

Official source

Lenalidomide: dispensing checks revised; handling precautions remain

ANSM · ANSM update 19/11/2026

In its 19 November update, ANSM states that Arrow has introduced corrective measures including visual inspection of each blister. Systematic visual inspection by pharmacists is therefore no longer required and boxes may be dispensed without opening them first. Gloves, careful removal and disposal, handwashing, and restrictions on handling by pregnant women or women of childbearing potential remain. The original article and attached letters date from November 2025.

Official source · Document 1 · Document 2

Randox LP(a) calibrators: erroneous patient results

ANSM · R2634811

ANSM published recall R 2634811 on 20 November. Randox’s 11 November letter concerns batch 899841, component lots 1955 LP–1959 LP: cloudy vials can distort calibration and patient results. Stop using and discard affected stock; assess prior results against the clinical picture and local laboratory procedures.

Official source · Document 1

Raz chairs: affected seats may break

ANSM · R2634261

ANSM’s 20 November notice links to FSN 2611-04 dated 17 November. Certain moulded/VFI seats supplied with Raz chairs may break and cause injury. Stop using a chair fitted with an affected seat and arrange replacement through the supplier. The annex identifies affected French serial numbers; no incidents or customer complaints had been reported as of 4 November.

Official source · Document 1

Likorall lifts: motor-shaft and safety-system failure

ANSM · R2630426

Baxter/Liko’s FA-2026-020 correction addresses possible motor-shaft failure combined with impaired Single Fault Safety braking. A rare double failure can cause rapid descent or a fall; one serious injury is reported. Arrange inspection/correction and follow the interim transfer precautions. The separate letter recalls the labelled ten-year service life. ANSM posted the 16 November letters on 19 November.

Official source · Document 1

Relay and TREO systems: endotoxin-related withdrawal

ANSM · R2633382

ANSM published Terumo Aortic’s FSN 2026-003 TAG Rev.01 covering all unexpired RelayPlus, RelayPro and TREO systems, including custom devices. Potential endotoxin contamination can cause inflammatory reactions, including serious complications. Stop use, quarantine and return affected stock. Follow the letter’s monitoring advice for implanted patients. Complaints include four deaths, but the manufacturer states that causation is not established; a link cannot be excluded.

Official source · Document 1

Cardiosave D.03: automatic purge may interrupt treatment

ANSM · R2633199

The French notice concerns a D.03 software problem that can trigger an automatic-purge failure alarm and prevent therapy from starting or resuming. A delay or interruption can cause serious harm. Follow the troubleshooting instructions, ensure backup support and observe the recommendation against interhospital transfers pending correction. This differs from the Canadian reversed-capacitor notice. The French covering letter is dated 17 November; the attached manufacturer notice is dated October 2026.

Official source · Document 1

Xpert MRSA/SA SSTI: false-negative results

ANSM · R2634622

ANSM’s notice and Cepheid’s letter cover batches 1001489295 (17701) and 1001491097 (17901). False-negative results can contribute to inappropriate or delayed treatment, potentially allowing infection to progress to bloodstream infection or sepsis. Stop using the affected kits and follow the disposal/replacement instructions. ANSM posted the 4 November letter on 19 November.

Official source · Document 1

Cardiosave: reversed-polarity capacitors

Health Canada · RA-82982

Some power-management or solenoid-control boards may contain reversed-polarity capacitors. Degradation can cause charging failure, failure to power on, interruption of therapy or unexpected shutdown. This Canadian Type II recall concerns models 0998-00-0800-53 and -65; obtain serial-number details and instructions from the manufacturer. Published on 19 November 2026; recall commencement: 2026-11-16.

Official source

Bridge Prep Kit: guidewire interaction

Health Canada · RA-82981

The Bridge occlusion balloon catheter may meet resistance when advanced over the supplied 0.035-inch InQwire Amplatz guidewire. Unexpired kit lots are affected. Health Canada records a Type II recall and directs users to the manufacturer. The balloon itself is within specification and is not affected when used with a conforming guidewire. Published on 19 November 2026; recall commencement: 2026-11-11.

Official source

Olympus ultrasound gastrovideoscopes: reprocessing instructions

Health Canada · RA-82980

Olympus is providing updated manual reprocessing instructions and training for GF-UC 140 P-AL 5 devices used with Aloka ultrasound processors. The update clarifies processing of complex features in line with current guidelines. Health Canada lists this as a Type II recall; use the manufacturer’s revised instructions. Published on 19 November 2026; recall commencement: 2026-11-06.

Official source

Portex tubes: resin/plasticizer variability

Health Canada · RA-82977

Health Canada’s Type I recall concerns specified Portex uncuffed tracheal-tube models and lots. A manufacturing issue involving variability in the plasticizer proportion may make some units softer. Identify affected stock using the official model list and manufacturer lot information; contact the manufacturer for instructions. Published on 19 November 2026; recall commencement: 2026-11-17.

Official source

VascuPuncture: coating particles and embolic risk

Health Canada · RA-82976

Hydrophilic guidewire coating may swell inconsistently in saline, clump and detach. Released particles may enter the bloodstream and cause embolic events. The Type I recall covers models 18070280 NW-05 MHP and 18145280 NW-05 MHP. Stop use, quarantine affected stock and follow return instructions. Published on 19 November 2026; recall commencement: 2026-10-27.

Official source

Medline saline syringes: microbial test result

Health Canada · RA-82975

Health Canada lists a Type I recall for EMZ 111240, 10 mL saline in a 10 mL flush syringe, lots 24 IJA 014 and 24 IJA 137. Routine testing found an out-of-specification microbial result in lot 24 IJA 137. Contact the manufacturer for the recall instructions. The notice does not establish that every syringe or the wider product portfolio is affected. Published on 19 November 2026; recall commencement: 2026-11-16.

Official source

PleurX kits: sterile-barrier integrity

Health Canada · RA-82974

Outer-packaging defects may compromise the sterile barrier of PleurX drainage kits, catalogue 50-7510, lot 1663598. Health Canada’s Type II recall instructs customers to stop using affected lots, inspect all inventory locations and destroy affected units according to facility procedures. Published on 19 November 2026; recall commencement: 2026-11-05.

Official source

Imported BUPISEN: ampoule and handling differences

Health Canada · RA-82954

Health Canada permits temporary importation of the Italian-authorized 7.5 mg/mL product during a shortage. It comes in 3 mL ampoules rather than the Canadian 2 mL ampoules and has Italian-only labels. It must not be re-sterilized by autoclaving. Healthcare professionals should check all differences and consult the Canadian monograph and the official communication before intrathecal administration.

Official source

Aptiva CTD: paediatric use and shelf life corrected

TGA · RC-2026-RN-00906-1

Werfen removed the paediatric claim because performance data are insufficient and reduced shelf life from 24 to 12 months. Use outside the supported conditions may give incorrect results. Stop testing paediatric samples and use the updated IFU. The notice states that no related complaints/adverse events were reported and routine retrospective review of paediatric results is not required. Action commenced on 18 November 2026.

Official source

Artisan Reticulin: weak or absent staining

TGA · RC-2026-RN-00958-1

Specific lots of AR 17911-2, AR 17911-5 and AR 18211-2 may show weak, absent or inconsistent staining. Possible consequences include false negatives, testing delays or re-biopsy if tissue is exhausted. Required run controls and pathologist review improve detectability. Discard affected kits and follow Agilent’s replacement instructions. Action commenced on 18 November 2026.

Official source

Corpuls: ongoing shock and reboot concerns

TGA · RC-2026-RN-00950-1

TGA’s Class I product alert describes ongoing shock-performance and reboot concerns following earlier actions. Four further issues are under investigation: end-tidal CO₂ inaccuracies, ECG transmission delays, failure to recognise STEMI and heart-rate discrepancies. Users should follow and maintain awareness of the specific customer letter. Action commenced on 18 November 2026.

Official source

My Immune Cold + Flu: consumer recall

TGA · RC-2026-RN-00896-1

TGA records a Class I consumer recall of batch 45201, expiry December 2027. It links the action to continued anaphylaxis reporting for Andrographis-containing medicines and removal of the ingredient from the permissible-ingredients determination. No adverse events had been reported for this particular product. Consumers should stop using affected stock and arrange return/refund. Action commenced on 18 November 2026.

Official source

Three Andrographis products: Class I recall

TGA · RC-2026-RN-00951-1

TGA’s Class I consumer recall covers all unexpired batches of Xiao Yan Li Dan Tablet, High Strength Chuan Xin Lian Antiphlogistic Tablet and Lian Zhi Xiao Yan Antiphlogistic Capsule. The official reason is the sustained reporting of anaphylaxis with Andrographis-containing listed medicines and removal of that ingredient from the permissible-ingredients determination. Stop supply/use of the affected products and follow the sponsor’s return/refund instructions. Action commenced on 18 November 2026.

Official source

Luna G3 BPAP: Targeted VT pressure-data correction

FDA · FDA company recall notice; UDI-DI 06948538365731

FDA posted React Health’s updated correction notice on 19 November; the company update is dated 17 November and the original notification was 8 October. Incorrect historical pressure statistics with Targeted VT enabled may lead clinicians to make inappropriate adjustments or delay therapy. The company reports 15 complaints and two serious adverse reports. Patients should contact their provider and should not independently change settings or discontinue respiratory therapy. Follow the professional correction instructions and serial-number appendix.

Official source · Document 1

Japan: English safety bulletin No.432 released

PMDA/MHLW · PMDSI No.432; September2026

PMDA announced the English version on 20 November; the bulletin itself is dated September 2026. Its lead article explains the August acetaminophen-precaution revision concerning high-anion-gap metabolic acidosis related to pyroglutamic-acid accumulation in susceptible patients. Another article covers labelling and brand-name measures to prevent medication errors. It also contains important safety information, precaution revisions and an early post-marketing vigilance list. These are earlier Japanese measures newly available in English, not new November signals.

Official source

BD Connecta: fluid-path separation

Medsafe · Medsafe 37990

Insufficient solvent during manufacture can allow tubing to separate from the male luer. Leakage can cause under-infusion or interruption of treatment, exposure to hazardous fluids, infection or air embolism. The affected six lots of product 394995 are listed by Medsafe; the recall requires destruction. Action commencement: 18 November 2026.

Official source

NeuroWorks/SleepWorks: live EEG display differences

Medsafe · Medsafe 37995

Medsafe records a software correction following a report that live EEG at a remote station differed from the acquisition computer and subsequent study review. The issue is limited to version 10.0.0 used with the SD PLUS FLEXI amplifier. The recorded action is a software upgrade; use the manufacturer’s instructions for the affected configuration. Action commencement: 18 November 2026.

Official source

ROTAFLOW: battery charging may stop

Medsafe · Medsafe 38002

During validation of replacement batteries, the manufacturer identified that the ROTAFLOW console may stop charging after battery mode has been used. Medsafe records a software upgrade for affected marketed products from 2005 through 31 December 2020; follow the recalling organisation’s correction instructions. Action commencement: 18 November 2026.

Official source

Cranial EM: registration problems in young children

Medsafe · Medsafe 37983

With Universal Atlas 6.0, Cranial EM surface-matching registration may fail or yield unusable results in neonates under 29 days and infants under 2 years. Affected versions 1.0 and 1.1.1–1.1.5 require a software upgrade according to the Medsafe entry. Action commencement: 17 November 2026.

Official source

Mammography systems: unexpected C-arm freefall

Medsafe · Medsafe 37988

Medsafe records a New Zealand correction for Hologic 3Dimensions and Selenia Dimensions mammography systems for potential sudden freefall caused by significant wear of the C-arm vertical-lift nut. The action is manufacturer advice regarding use. This is the New Zealand action for an issue also reported by TGA; it is not counted as a separate newly identified worldwide signal. Action commencement: 17 November 2026.

Official source

New Zealand: LP(a) calibrator recall

Medsafe · Medsafe 37989

Medsafe’s national recall covers batch 899841, lots 1955 LP–1959 LP. Cloudy vials can affect calibration and patient results even when calibration passes. Stop using the affected set; the recorded action is destruction. The same product issue is described in the French notice, with the New Zealand action recorded separately. Action commencement: 17 November 2026.

Official source

New Zealand: Xpert false-negative recall

Medsafe · Medsafe 37957

Medsafe’s entry covers batch 1001489295, lot 17701, expiry 4 July 2027. False negatives may delay appropriate treatment and allow infection to progress, potentially to bloodstream infection and sepsis. The national action is destruction. The French communication covers this lot and an additional lot; their scopes should not be conflated. Action commencement: 12 November 2026.

Official source

Dual IBP Adapter: defibrillation protection

Medsafe · Medsafe 37959

The adapter may not provide adequate defibrillation protection with incompatible, non-defibrillation-proof transducers. Energy may be diverted through the IBP system instead of the patient. Medsafe records updated instructions for use for model 989803199741. Use only compatible transducers as listed by the manufacturer. Action commencement: 12 November 2026.

Official source

Sepalna: first published product information

EMA · EMEA/H/C/006708; initial PI

EMA first published the initial product information for Sepalna on 19 November, following EU authorisation on 12 November. Senaparib is under additional monitoring. The document includes blood-count monitoring and dose-interruption/reduction instructions for haematological toxicity, other safety precautions and interaction management. Healthcare professionals should use the complete approved information. This is initial safety information for a newly authorised medicine, not a newly detected post-marketing signal.

Official source · Document 1

Professional relevance

QPPV, LQPPV and LCPPV teams may use this review when assessing local safety information and risk-minimisation measures. Role applicability and duties vary by jurisdiction. A national action should not automatically be applied elsewhere.